Condition: Myeloma · Sponsor: Nantes University Hospital
The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.
This description comes directly from the study's public registry record.
Caroline Bodet-Milin, MD · 33240084136 · caroline.milin@chu-nantes.fr
Always discuss trial participation with your own doctor first.
| CHU d'Angers | Angers, France | Recruiting |
| CHU de Brest | Brest, France | Recruiting |
| CHU de Caen | Caen, France | Recruiting |
| CHU de Nantes | Nantes, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Withdrawn |
| CHU de Rennes | Rennes, France | Withdrawn |
| CHU de Tours | Tours, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03832127